arrow
E

E. Maubec

université paris 13
H指数:39
被引数:5,970

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study
2026-01-010
OA
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)

COVID-19疫情对黑色素瘤的影响:一项来自法国黑色素瘤患者临床数据库(RIC-Mel)的回顾性研究

2025-09-040
PRE
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL)

Nardin C,Cavalieri C,Lebbé C,Gérard E,Puyraveau M,Vergara R,等人. 可切除III/IV期黑色素瘤患者的新辅助免疫检查点抑制剂治疗:一项法国全国性真实世界研究(NEOMEL). 英国皮肤病学杂志. (2025) 7:ljaf268. doi: 10.1093/bjd/ljaf268.

2025-07-140
PRE
Increased risk of cutaneous squamous cell carcinomas in patients with Sézary syndrome: A nationwide multicenter retrospective study

Sézary综合征患者皮肤鳞状细胞癌风险增加:一项全国多中心回顾性研究

2025-03-220
OAAI
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study (vol 73, 102679, 2024)
2025-01-010
OAAI
Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study
CANCER
IF5.1
2024-12-080
PRE
When to stop immunotherapy for advanced melanoma: the emulated target trials

何时停止晚期黑色素瘤的免疫治疗: 模拟的目标试验

2024-12-010
PRE
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab plus nivolumab vs. nivolumab in a real-world setting

在真实世界环境中,ipilimumab 联合 nivolumab 与 nivolumab 单药治疗转移性黑色素瘤的一线疗效与安全性比较

2024-11-280
PRE
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
2024-09-011
PRE
Real-life ef fi cacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
2024-07-013
OAAI
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network
2024-06-120
OAAI
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
2023-12-016
OAAI
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)
2023-10-234
OAAI